Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.
Christina M. Annunziata, MD, PhD
Advertisement
Articles by Christina M. Annunziata, MD, PhD
Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Annunziata on Efforts to Prevent Gynecologic CancersPublished: August 15th 2017 | Updated:
Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian CancerPublished: March 15th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5